论文部分内容阅读
目的探讨间插治疗模式是否可延长经EGFR-TKIs治疗的晚期非小细胞肺癌(NSCLC)缓慢进展后患者的无进展生存期(PFS)。方法收集2009年8月至2014年12月就诊于江苏省肿瘤医院的EGFR-TKIs治疗后缓慢进展的晚期NSCLC患者24例,均采用化疗药物和EGFR-TKIs间插治疗模式进行治疗。比较EGFR-TKIs治疗至缓慢进展的PFS及EGFR-TKIs治疗至间插治疗模式进展后的PFS。随访至2015年4月30日,绘制中位PFS生存曲线图。结果 22例患者可评估中位PFS,EGFRTKIs治疗至缓慢进展的中位PFS为13.3个月,EGFR-TKIs治疗至间插治疗模式进展的中位PFS为24个月(P<0.001)。结论晚期NSCLC患者经EGFR-TKIs治疗后发生缓慢进展时,采用化疗药物和EGFR-TKIs间插治疗模式可显著延长患者的中位PFS。
Objective To investigate whether the intervenous treatment model can prolong the progression-free survival (PFS) of patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR-TKIs. Methods Twenty-four patients with advanced NSCLC who progressed slowly after EGFR-TKIs treatment at Cancer Hospital of Jiangsu Province from August 2009 to December 2014 were recruited. Chemotherapy and intercalary EGFR-TKIs therapy were collected. PFS was compared between treatment of EGFR-TKIs to progression-slowing PFS and EGFR-TKIs until progression of intercourse therapy. Follow-up to April 30, 2015, plotted median PFS survival. Results The median PFS was assessed in 22 patients. The median PFS for EGFRTKIs progression to progression was 13.3 months. The median PFS for progression from EGFR-TKIs to intervening therapy was 24 months (P <0.001). Conclusions When slow progression of EGFR-TKIs occurs in patients with advanced NSCLC, the median PFS may be significantly prolonged by intervening chemotherapy with EGFR-TKIs.